IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy
about
Hepatitis C and HIV co-infection: new drugs in practice and in the pipelineThe cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patientsRelating human genetic variation to variation in drug responses.Pharmacogenomics of hepatitis C infections: personalizing therapy.In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use.Challenges for HCV vaccine development in HIV-HCV coinfection.IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.The role of pharmacogenetics in the treatment of chronic hepatitis C infection.Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management.EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C.IL28B rs12980275 polymorphism shows association with response to treatment in Pakistani patients with chronic hepatitis C.Prevalence of IL-28B and ITPA genotypes in Chinese Han population infected persistently with hepatitis C virus genotype 6 or HCV-1.Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.
P2860
Q27022596-3E72E6E7-17AA-49D9-ACC1-1762B9147B38Q33710740-E2140B2C-7CC7-4F18-BDA9-0AF13FC7D1F0Q34157284-C8DD9D5A-B6C9-4F73-B3AD-1E1DE3C3C7D3Q36252524-FFD32C7D-D78F-4E77-BB3B-924C4C31AD65Q36632938-F02E7478-8038-4FCB-A27D-4EB983A09965Q37016495-232068BD-61AC-4CC8-8320-28FD67340FCCQ38036684-8B8C5536-6BD1-4593-B4D7-8C4575BB410EQ38053543-E117A354-7D1F-40DB-853A-F982BDD2B83CQ38151586-CD5D7F1D-E8A1-40E2-9278-52CCCD41D923Q38180719-BFD0C2F8-9150-4CF2-B684-14906A56C24BQ40124597-5B80F049-9297-4F16-A95F-5E72264563FBQ41503237-663EDAD5-5985-49C9-91C5-6529557FBB25Q42252312-95FBE189-D6C0-4CA0-84F2-95147FB788ECQ44369266-2A061A2C-4577-4AEC-A866-64567FB43B68
P2860
IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
IL28B alleles exert an additiv ...... terferon and ribavirin therapy
@ast
IL28B alleles exert an additiv ...... terferon and ribavirin therapy
@en
IL28B alleles exert an additiv ...... terferon and ribavirin therapy
@nl
type
label
IL28B alleles exert an additiv ...... terferon and ribavirin therapy
@ast
IL28B alleles exert an additiv ...... terferon and ribavirin therapy
@en
IL28B alleles exert an additiv ...... terferon and ribavirin therapy
@nl
prefLabel
IL28B alleles exert an additiv ...... terferon and ribavirin therapy
@ast
IL28B alleles exert an additiv ...... terferon and ribavirin therapy
@en
IL28B alleles exert an additiv ...... terferon and ribavirin therapy
@nl
P2093
P2860
P1433
P1476
IL28B alleles exert an additiv ...... terferon and ribavirin therapy
@en
P2093
Aids Clinical Trials Group A5178 Study Team
Barham K Abu Dayyeh
Kenneth E Sherman
Namrata Gupta
Paul I W de Bakker
P2860
P304
P356
10.1371/JOURNAL.PONE.0025753
P407
P577
2011-10-07T00:00:00Z